They include high expression of estrogen and progesterone receptor (ER + , PR +), HER2 + (HER2 high/overexpressed), and triple-negative breast cancers (TNBC; ER-, PR-, HER2-) [6]. Here, PGR is linked to triple-negative breast carcinoma.